Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
62°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
117.31
-5.38 (-4.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
September 17, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Announces Health Canada Approves its COVID-19 Vaccine
September 16, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Highlights New Clinical Data on its COVID-19 Vaccine
September 15, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
September 09, 2021
From
Moderna, Inc.
Via
Business Wire
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
September 08, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
September 07, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
September 03, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna to Present at Upcoming Investor Conferences in September 2021
September 02, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
September 01, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
August 25, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna to Host Virtual R&D Day on Thursday, September 9, 2021
August 24, 2021
From
Moderna, Inc.
Via
Business Wire
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
August 19, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024
August 16, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
August 16, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
August 13, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months
August 12, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
August 10, 2021
From
ModernaTX, Inc.
Via
Business Wire
Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine
August 09, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Named Fast Company’s 2021 Best Workplace for Innovators
August 06, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
August 05, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)
August 03, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
August 02, 2021
From
Moderna, Inc.
Via
Business Wire
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union
July 23, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces Establishment of New Charitable Foundation
July 22, 2021
From
Moderna, Inc.
Via
Business Wire
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
July 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023
July 22, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022
July 20, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna to Report Second Quarter Financial Results on Thursday, August 5, 2021
July 15, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine
July 12, 2021
From
Moderna, Inc.
Via
Business Wire
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
July 07, 2021
From
Moderna, Inc.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.